Insider buying
~$360K88K sh @ $4.07
Traded May 27 · filed 2 days later
Since the trade −33.5% · S&P 500 −1.4% · to Nov 16
The CEO of Polaryx Therapeutics paid $360K out of pocket for Polaryx Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PLYX · NASDAQ · Pharmaceutical Preparations
Polaryx Therapeutics (PLYX) · oqro.io/stocks/PLYX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.67−0.10 (−5.65%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
No open-market purchase by an insider of Polaryx Therapeutics was filed in the last 90 days. The latest on record was on May 29, 2026.
Since 2026, Polaryx Therapeutics insiders reported 2 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Polaryx Therapeutics (PLYX) was filed with the SEC in the last 90 days.
No trade in Polaryx Therapeutics (PLYX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−95.2% (−$33.33) from Feb 2, 2026 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $35.00 on Feb 2, 2026 to $1.67 on Nov 16, 2026 (−95.2%). Disclosed in this range: 2 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Paramus, Nj.
Last 12 months
Not enough history
Market value
$88.2M
Short interest: 138K shares sold short (0.3% of shares outstanding), +16.9% vs the previous count, 6.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $8.44M, at Sep 30, 2026
Net income, last 12 months
−$8.75M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Insider buying
Traded May 27 · filed 2 days later
Since the trade −33.5% · S&P 500 −1.4% · to Nov 16
The CEO of Polaryx Therapeutics paid $360K out of pocket for Polaryx Therapeutics shares.
Insider buying
Traded Feb 18 · filed 2 days later
Since the trade −42.2% · S&P 500 +7.8% · to Nov 16
The CFO of Polaryx Therapeutics paid $8K out of pocket for Polaryx Therapeutics shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Polaryx Therapeutics reported 2 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $368K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in lysosomal storage disorders. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Polaryx Therapeutics over the 12 months to Nov 17, 2026: 1 clinical trial.